ArticlePlastic and reconstructive surgery. Global open2026
Preliminary Investigation and Safety Profile of a Novel Hybrid Filler (Hyaluronic Acid-Calcium Hydroxylapatite) in Asian Facial Rejuvenation.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study.International journal of molecular sciences · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable fillers, such as hyaluronic acid (HA)-based fillers and calcium hydroxylapatite (CaHA) collagen stimulators, have been used to replenish lost volume by physically filling gaps or stimulating collagen synthesis. A commercially available hybrid filler combining HA and CaHA in a new gel-form collagen stimulator has yet to be extensively studied in an Asian population. This was a case series of patients attending 2 centers in Hong Kong between August 2023 and February 2024 to document the safety of HA-CaHA in Asian patients. Outcomes included patients' overall satisfaction with the treatment experience, based on the Global Aesthetic Improvement Scale assessment and treatment-emergent adverse events reported after treatment at the 3- and 6-month follow-ups. Twenty-five Chinese patients (22 female; age range [median]: 25-63 [37] y) received 2-3 syringes of HA-CaHA with a mean total volume of 2.8 mL (range: 2.5-3.75 mL). Immediately after treatment and at the 1- and 3-month follow-ups, 60% (15 of 25) of patients reported "very much improved," 32% (8 of 25) reported "much improved," 8% (2 of 25) reported "improved," and 0% reported "unchanged" or "worse" throughout the 6 months. Treatment-emergent adverse events immediately after treatment included bruising (n = 3, 12%), edema (n = 8, 32%), erythema (n = 1, 4%), tenderness (n = 3, 12%), and skin induration (n = 4, 16%). A hybrid filler combining HA and CaHA represents a promising advance in facial rejuvenation, offering immediate volumizing effects, longer-lasting results, and few adverse events.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.